Ascend Gene & Cell Therapies announces today that it has launched as a facilitator for gene therapy companies to help translate product ideas into viable clinical programs. Originally founded by Monograph Capital, Ascend has raised a total of $132.5M, most recently completing a Series A fundraise led by Abingworth and Petrichor. This fundraising has enabled the acquisition of CMC capabilities and technologies from Freeline Therapeutics. Source: PR Newswire 9/5/2023